Back to top
more

Minerva Neurosciences (NERV)

(Delayed Data from NSDQ)

$2.53 USD

2.53
4,586

+0.09 (3.79%)

Updated Apr 23, 2024 03:59 PM ET

After-Market: $2.49 -0.04 (-1.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Sanghamitra Saha headshot

Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners

by Sanghamitra Saha

Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.

What Makes Minerva Neurosciences (NERV) a New Buy Stock

by Zacks Equity Research

Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

by Zacks Equity Research

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More

by Zacks Equity Research

Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.

Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up

by Zacks Equity Research

Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.

Here's Why Minerva Neurosciences (NERV) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel

by Zacks Equity Research

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.

Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study

by Zacks Equity Research

Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.

AlloVir (ALVR) Begins Study to Prevent Six Viral Infections

by Zacks Equity Research

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.

Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder

by Zacks Equity Research

The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.

Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 40% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of -47.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Minerva Neurosciences (NERV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cerevel (CERE) Novel Schizophrenia Drug Succeeds in Phase I

by Zacks Equity Research

Cerevel Therapeutics (CERE) surges as schizophrenia candidate, CVL-231, demonstrates clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks in phase Ia study.

Sage Stock Declines on Late-Stage Depression Study Data

by Zacks Equity Research

Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.

Minerva Neurosciences (NERV) Enters Overbought Territory

by Zacks Equity Research

Minerva Neurosciences (NERV) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen

Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More

by Zacks Equity Research

The biotech sector was in focus last week with earnings updates from Regeneron (REGN) and Moderna (MRNA) and regulatory updates from Amgen, among others.

Minerva (NERV) Soars on Promising Schizophrenia Study Data

by Zacks Equity Research

Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boosts investors' sentiment.

Zacks Small-Cap Research headshot

Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock?

by Zacks Small-Cap Research

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

Kinjel Shah headshot

4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty

by Kinjel Shah

There is uncertainty about the impact of the coronavirus pandemic on the Zacks Medical-Drugs industry. However, with demand trends expected to improve in the second half of 2020, SAVA, KMPH, NERV, ALDX may prove to be good additions to the portfolio.